相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
Atsuyuki Igarashi et al.
JOURNAL OF DERMATOLOGY (2012)
High incidence of intolerance to tuberculosis chemoprophylaxis
Muhammad Haroon et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
Tsen-Fang Tsai et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2011)
Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients
A. I. Sanchez-Moya et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
I. Solovic et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Targeting IL-23 in human diseases
Mario M. D'Elios et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment
Marie-Gaelle Bray et al.
JOINT BONE SPINE (2010)
Tuberculosis 4 Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
Robert S. Wallis et al.
LANCET (2010)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians
A. Perlmutter et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents
Sean D. Doherty et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Tuberculosis in the age of biologic therapy
Claudia Hernandez et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection
Juan J. Gomez-Reino et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Inborn errors of IL-12/23- and IFN-γ-mediated immunity:: molecular, cellular, and clinical features
Orchidee Filipe-Santos et al.
SEMINARS IN IMMUNOLOGY (2006)
TNF-blocking agents and tuberculosis: new drugs illuminate an old topic
J Keane
RHEUMATOLOGY (2005)
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
L Carmona et al.
ARTHRITIS AND RHEUMATISM (2005)
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis
D Yee et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
MA Gardam et al.
LANCET INFECTIOUS DISEASES (2003)
分享论文
